Document is current
Any future updates will be listed below
-
Authors
Fielden, John
Siegner, Sebastian M.
Gallagher, Danielle N. https://orcid.org/0000-0001-5832-652X
Schröder, Markus S. https://orcid.org/0000-0001-5942-1254
Dello Stritto, Maria Rosaria https://orcid.org/0000-0002-3899-8051
Lam, Simon https://orcid.org/0000-0002-4476-0971
Kobel, Lena https://orcid.org/0000-0001-7949-141X
Schlapansky, Moritz F. https://orcid.org/0000-0001-6072-7840
Jackson, Stephen P. https://orcid.org/0000-0001-9317-7937
Cejka, Petr https://orcid.org/0000-0002-9087-032X
Jost, Marco https://orcid.org/0000-0002-1369-4908
Corn, Jacob E. https://orcid.org/0000-0002-7798-5309
- License Information
-
More Information
Article History
Received: 10 July 2023
Accepted: 19 February 2025
First Online: 9 April 2025
Competing interests
: J.E.C. is a cofounder and scientific advisory board (SAB) member of Serac Biosciences; an SAB member of Mission Therapeutics, Relation Therapeutics and Hornet Biologicals; and a consultant for Cimeio Therapeutics. S.P.J. is shareholder and part-time chief research officer of Insmed Innovation UK, board member and chair of scientific advisory board for Mission Therapeutics and a founding partner of Ahren Innovation Capital. All other authors have no competing interests.
